S102 – Mometasone Furoate Reduces Severity of Adenoidal Hypertrophy

Objectives Allergic rhinitis (AR) is a risk factor for adenoidal hypertrophy—the adenoids are the lymphoid tissue closest to the nasal mucosa—and results in upper airway obstruction and snoring. The efficacy of mometasone furoate nasal spray (MFNS) in reducing gland size and degree of snoring in subjects with adenoidal hypertrophy and concomitant AR was assessed. Methods Children 5 to 10 years old with adenoidal hypertrophy and a history of chronic nasal obstruction and snoring received MFNS 50 mcg QD in each nostril. 16 subjects with AR diagnosed by positive skin prick test to environmental allergens comprised the treatment group, and 8 subjects with no history of AR and a negative skin prick test comprised the control group. Efficacy variables, assessed at Weeks 0 (baseline), 4, and 8, were change in size of the adenoid gland, evaluated by flexible fiber‐optic and graded as a percentage according to degree of obliteration of the choanae, and change in degree of snoring, evaluated on a 3‐point scale (0 absent, 1 intermittent, or 2 continuous). Results Significant improvements in the treatment group vs. baseline at Week 8 were an 84% decrease in mean average adenoidal‐tissue size, compared with a 5% decrease in the control group (P less than 0.05) and an 80% decrease in snoring compared with a 5% decrease in the control group (P less than 0.05). Conclusions Once‐daily MFNS 50 mcg is beneficial in the treatment of adenoidal hypertrophy and in reducing snoring in pediatric patients with AR.